A Comparative Study of Entecavir vs Adefovir Plus Lamivudine vs Combination Entecavir Plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Chinese Subjects.

Trial Profile

A Comparative Study of Entecavir vs Adefovir Plus Lamivudine vs Combination Entecavir Plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Chinese Subjects.

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 03 Sep 2015

At a glance

  • Drugs Adefovir (Primary) ; Entecavir (Primary) ; Lamivudine
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 12 Dec 2009 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 04 Dec 2009 Planned initiation date changed from Nov 2009 to Dec 2009 as reported by ClinicalTrials.gov.
    • 28 Oct 2009 Planned initiation date changed from 1 Dec 2009 to 1 Nov 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top